

Imugene Receives Institutional Review Board approval from the Taipei Veterans General Hospital in Taiwan for Study in Gastric Cancer

- **Institutional Review Board of Taipei Veterans General Hospital (Taiwan) Approves HER-Vaxx Phase Ib/2 Study in Gastric Cancer.**
- **This follows the University of Hong Kong Institutional Review Board Approval in July.**
- **Principal Investigators include Dr Yee Chao and Dr Chia-Jui Yen of Taiwan.**

Melbourne, Australia, 11 August 2016: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that it has received approval from the Institutional Review Board of the Taipei Veterans General Hospital in Taiwan for the Phase 1b/2 study of its HER-Vaxx immuno-oncology therapy in gastric cancer.

This approval from the Ethics Committee positions Imugene to enrol patients in the Phase 1b/2 in HER2 positive gastric cancer study within the coming months. Completing another major milestone underscores HER-Vaxx's re-entry into the clinic with the Phase 1b/2 in HER2 positive gastric cancer study. Gastric cancer represents an area of high unmet medical need, particularly in Asia.

The proposed HER-Vaxx Phase 1b/2 study will be conducted in two parts. The initial Phase 1b will enrol up to 18 patients to be treated with HER-Vaxx in combination with chemotherapy to interrogate three dose levels. This first stage will provide safety data, immunogenicity data (a measure of how many of the HER2 cancer fighting antibodies are produced), evaluate the booster schedule and determine the optimal recommended Phase 2 dose (RP2D) to take into the Phase 2 study.. The larger open label Phase 2 study will recruit around 68 patients randomised into two arms of either HER-Vaxx plus standard-of-care or standard-of-care alone.

Imugene's Chief Operating Officer, Leslie Chong states, "I am thrilled to be working with Dr. Yee Chao from the Taipei Veterans General Hospital as he is one of the most experienced gastric oncologists with noted expertise in anti-HER2 cancer therapies. With another milestone met, we are ever closer to providing much needed therapy to our patients and to obtaining valuable data for Imugene. I thank my clinical development team in continuing to do great work and for their dedication for the successful re-entry of HER-Vaxx into the clinic in 2016".

The trial details are listed on the ClinicalTrial.gov website.

Identifier: NCT02795988

Link: <https://clinicaltrials.gov/show/NCT02795988>

About Imugene

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and

validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

In January 2016 Imugene announced a new partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies..

For further information, please visit www.imugene.com.

Sign up to follow @TeamImugene on Twitter at <http://www.twitter.com/TeamImugene>.

To follow Imugene on Facebook visit www.facebook.com/imugene.

For further information please contact:

Imugene:

Leslie Chong, Chief Operating Officer

Tel: +61 458 040 433 (Australia), [leslie.chong\[at\]imugene.com](mailto:leslie.chong[at]imugene.com)